Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma-Reference-Cited by-同舟云学术

Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

Published:2024-06 Issue: Volume: Page:
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Sternberg Cora N.,Loriot Yohann,Choy Ernest,Castellano Daniel,Lopez-Rios Fernando,Banna Giuseppe Luigi,Zengerling Friedemann,De Giorgi Ugo,Gedye Craig,Masini Cristina,Bamias Aristotelis,Garcia del Muro Xavier,Duran Ignacio,Powles Thomas,Retz Margitta,Gamulin Marija,Geczi Lajos,Huddart Robert A.,Calabrò Fabio,Kandula Geetha,Skamnioti Pari,Merseburger Axel S.

Funder

F. Hoffmann-La Roche

F Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Reference24 articles.

1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017

3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018

4. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial;van der Heijden;Eur Urol,2021

5. Roche. TECENTRIQ (atezolizumab) summary of product characteristics. Grenzach-Wyhlen, Germany: Roche Registration GmbH; 2023.